Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Filter by Pathway Type:



Showing 64991 - 65000 of 605359 pathways
SMPDB ID Pathway Name and Description Pathway Class Chemical Compounds Proteins

SMP0145343

Pw147011 View Pathway

13-cis-Retinoic acid Drug Metabolism Pathway

Metabolic

SMP0000575

Pw000551 View Pathway

11-beta-Hydroxylase Deficiency (CYP11B1)

11-beta-Hydroxylase Deficiency, also called congenital adrenal hyperplasia (CAH), is an autosomal recessive disorder and caused by a defective 11-beta-hydroxylase. 11-beta-hydroxylase catalyzes the conversion of cortexolone into cortisol which is useful for maintaining blood sugar levels and suppressing inflammation. This disorder is characterized by a large accumulation of cortexolone in the endoplasmic reticulum (ER). Symptoms of the disorder include abnormality of hair growth rate and menstrual cycle. It is estimated that 11-beta-hydroxylase deficiency affects 1 in 100,000 to 200,000 newborns.
Disease

SMP0125800

Pw127367 View Pathway

11-beta-Hydroxylase Deficiency (CYP11B1)

11-beta-Hydroxylase Deficiency, also called congenital adrenal hyperplasia (CAH), is an autosomal recessive disorder and caused by a defective 11-beta-hydroxylase. 11-beta-hydroxylase catalyzes the conversion of cortexolone into cortisol which is useful for maintaining blood sugar levels and suppressing inflammation. This disorder is characterized by a large accumulation of cortexolone in the endoplasmic reticulum (ER). Symptoms of the disorder include abnormality of hair growth rate and menstrual cycle. It is estimated that 11-beta-hydroxylase deficiency affects 1 in 100,000 to 200,000 newborns.
Disease

SMP0144686

Pw146354 View Pathway

1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) Drug Metabolism Action Pathway

Drug Action
  • 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

SMP0124716

Pw126201 View Pathway

1-Methylhistidine Metabolism

Methylhistidine is a modified amino acid that is produced in myocytes during the methylation of actin and myosin. It is also formed from the methylation of L-histidine, which takes the methyl group from S-adenosylmethionine and forms S-adenosylhomocysteine as a byproduct. After its formation in the myocytes, methylhistidine enters the blood stream and travels to the kidneys, where it is excreted in the urine. Methylhistidine is present in the blood and urine in higher concentrations after skeletal muscle protein breakdown, which can occur due to disease or injury. Because of this, it can be used to judge how much muscle breakdown is occurring. Methylhistidine levels are also affected by diet, and may differ between vegetarian diets and those containing meats.
Metabolic

SMP0127816

Pw129435 View Pathway

1-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone Adduct Drug Metabolism

Metabolic

SMP0145083

Pw146751 View Pathway

1,2-icosapentoyl-sn-glycero-3-phosphoserine Drug Metabolism Action Pathway

Drug Action
  • 1,2-icosapentoyl-sn-glycero-3-phosphoserine

SMP0145084

Pw146752 View Pathway

1,2-Distearoyllecithin Drug Metabolism Action Pathway

Drug Action
  • 1,2-Distearoyllecithin

SMP0144873

Pw146541 View Pathway

1,2-Benzodiazepine Drug Metabolism Action Pathway

Drug Action
  • 1,2-Benzodiazepine

SMP0130706

Pw132374 View Pathway

1,2-Benzodiazepine Drug Metabolism

1,2-Benzodiazepine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. 1,2-Benzodiazepine passes through the liver and is then excreted from the body mainly through the kidney.
Metabolic
  • 1,2-Benzodiazepine
Showing 64991 - 65000 of 65006 pathways